Rapid Regression of Chemotherapy Refractory Lymphocyte Predominant Hodgkin's Disease after Administration of Rituximab (anti CD 20 Monoclonal Antibody) and Interleukin-2

Ulrich Keilholz Dept. of Hematology/Oncology, Free University Berlin, Hindenburgdamm 30, 12200, Berlin, Germany

Hubert Szelényi Dept. of Hematology/Oncology, Free University Berlin, Hindenburgdamm 30, 12200, Berlin, Germany

Jan Siehl Dept. of Hematology/Oncology, Free University Berlin, Hindenburgdamm 30, 12200, Berlin, Germany

Hans Dieter Foss Dept. of Pathology, University Hospital Benjamin Franklin, Free University Berlin, Hindenburgdamm 30, 12200, Berlin, Germany

Wolfgang Knauf Dept. of Hematology/Oncology, Free University Berlin, Hindenburgdamm 30, 12200, Berlin, Germany

Eckhard Thiel Dept. of Hematology/Oncology, Free University Berlin, Hindenburgdamm 30, 12200, Berlin, Germany

References

von Wasielewski R, Mengel M, Fischer R, et al. Classical Hodgkin's disease. Clinical impact of the immunophenotype. Am J Pathol 1997; 151: 1123–1130
PubMed Web of Science ®Google Scholar
Stein H, Hummel M, Dürkop H, Foss H D, Herbst H. Biology of Hodgkin's disease. The Lymphomas, G P Canellos, T A Lister, J L Sklar. W. B. Saunders Company, Philadelphia 1998; 287–305, Chapter Fifteen
Google Scholar
McLaughlin P, Grillo-Lopez A J, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
PubMed Web of Science ®Google Scholar
Coiffier B, Haioun C, Ketterer N, et al. Rituximab (Anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998; 92: 1927–1932
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Rapid Regression of Chemotherapy Refractory Lymphocyte Predominant Hodgkin's Disease after Administration of Rituximab (anti CD 20 Monoclonal Antibody) and Interleukin-2

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Rapid Regression of Chemotherapy Refractory Lymphocyte Predominant Hodgkin's Disease after Administration of Rituximab (anti CD 20 Monoclonal Antibody) and Interleukin-2

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date